|Bid||9.82 x 2500|
|Ask||11.70 x 300|
|Day's Range||10.00 - 10.49|
|52 Week Range||8.03 - 12.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.00|
KB103 represents the first investigational HSV-1 based gene therapy for the severe skin disorder dystrophic epidermolysis bullosa to receive this designation. KB103 previously received Orphan Drug Designation ...
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s proprietary technology, the Skin TARgeted Delivery Platform, or the STAR-D platform. The presentation will take place at the annual World Orphan Drug Congress USA, being held in Oxon Hill, Maryland, April 25-27, 2018.
KB103 is an internally generated modified HSV-1 based gene therapy candidate engineered with a COL7A1 gene construct to treat Dystrophic Epidermolysis Bullosa. Therapeutic candidate formulated into a topical ...
IND for KB103 to treat Dystrophic Epidermolysis Bullosa to be filed in March 2018. IND for KB105 to treat Lamellar Ichthyosis to be filed in Q4 2018. Company was granted composition of matter and method ...
PITTSBURGH, March 05, 2018-- Krystal Biotech, Inc., a gene therapy company advancing“ off-the-shelf,” treatments for dermatological diseases, today announced that Krish Krishnan, Chief Executive Officer, ...
Krystal Biotech Inc (NASDAQ:KRYS), a USD$114.55M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...
President and CEO of Krystal Biotech Inc (NASDAQ:KRYS) Krish S Krishnan bought 100,000 shares of KRYS on 09/22/2017 at an average price of $10 a share.
Seven IPOs are scheduled to hit the public markets this week, including video streaming service Roku and specialty chemicals firm PQ Group, both valued at more than $1 billion before their IPOs.